Browsing Tag

ATH201

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

Eli Pacheco Apr 21, 2022 0

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20,…

Health

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Eli Pacheco Jan 19, 2022 0

SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of…

Health

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

Eli Pacheco Sep 30, 2021 0

SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in…

Health

Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in…

Eli Pacheco Jul 7, 2021 0

Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease SEATTLE, July 07,…